24,000,000 MYR which is equivalent to 196,537,120 THB at the exchange rate of 8.0548 THB per MYR on November 24, 2017 which prior to Board of Director’ Company. The exchange rate is referred to the Bank of
the same quarter of prior year by Baht 10.08 million or equivalent to 49.55%. For the 3 months period (quarter 2/2019), the Company has total revenues at Baht 1 35.78 million which increased compared to
decreased compared to the same quarter of prior year by Baht 17.26 million or equivalent to 62.79%. For the 3 months period (quarter 3 /2019), the Company has total revenues at Baht 146.68 million which
91.52%, which is based on the Criteria of Total Value of Consideration, which is the highest result. Including of the Company does not have any assets acquired or disposed of during the 6 months prior to
www.interpharma.co.th 6. Approve to present to the Shareholders' Meeting to consider and approve the issuance of debentures in the amount not exceeding 300 million Baht. The total debt burden of the Company at any one
decreased compared to the same quarter of prior year by Baht 5.51 million, resulting gross profit at Baht 4.65 million but the Company has total comprehensive loss at Baht 7.85 million. Since the revenues of
million Baht from last year. This would support the overall performance of the Company further in the future. In 2018, the Company was able to pursue a remarkably success in distress debt management
year. In 2017, the Company achieved a remarkably success in distress debt management business. The Company achieved its record high in cash collection at 1,847 million Baht. Thanks to distress the